Cleo Diagnostics (ASX:COV) EV-to-FCF : (As of May. 11, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cleo Diagnostics's Enterprise Value is A$23.85 Mil. Cleo Diagnostics does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Cleo Diagnostics's EV-to-FCF at this moment.

The historical rank and industry rank for Cleo Diagnostics's EV-to-FCF or its related term are showing as below:

ASX:COV' s EV-to-FCF Range Over the Past 10 Years
Min: -47.67 Med: 0 Max: 0
Current: -13.48

ASX:COV's EV-to-FCF is ranked worse than
100% of 363 companies
in the Medical Devices & Instruments industry
Industry Median: 27.99 vs ASX:COV: -13.48

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Cleo Diagnostics's stock price is A$0.175. Cleo Diagnostics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Cleo Diagnostics's PE Ratio at this moment.

Cleo Diagnostics EV-to-FCF Historical Data

The historical data trend for Cleo Diagnostics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics EV-to-FCF Chart

Cleo Diagnostics Annual Data

Trend

Jun23

EV-to-FCF

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
EV-to-FCF	-	-	-

Competitive Comparison of Cleo Diagnostics's EV-to-FCF

For the Medical Devices subindustry, Cleo Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's EV-to-FCF falls into.

Cleo Diagnostics EV-to-FCF Calculation

Cleo Diagnostics's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	23.848	/
	=

Cleo Diagnostics (ASX:COV) EV-to-FCF Explanation

Cleo Diagnostics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.175	/
	=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Cleo Diagnostics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines